|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12Q 1/68 | |
| A61P 25/18 |
| (11) | Patento numeris | 2430183 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10719224.7 |
| Europos patento paraiškos padavimo data | 2010-05-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-03-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-12-17 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/035045 |
| Data | 2010-05-15 |
| (87) | Numeris | WO 2010/132866 |
| Data | 2010-11-18 |
| (30) | Numeris | Data | Šalis |
| 178934 P | 2009-05-15 | US |
| (72) |
LAVEDAN, Christian, US
VOLPI, Simona, US
|
| (73) |
Vanda Pharmaceuticals Inc.,
2200 Pennsylvania Avenue Suite 300-E, Washington, DC 20037,
US
|
| (54) | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE |
| ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE |